PRX-03140

PRX-03140
Clinical data
ATC code	None;
Identifiers
	IUPAC name 4-hydroxy-7-isopropyl-6-oxo-N-[3-(1-piperidinyl)propyl]-6,7-dihydrothieno[2,3-b]pyridine-5-carboxamide;
CAS Number	869493-21-0;
PubChem CID	54677674;
ChemSpider	21377738;
CompTox Dashboard (EPA)	DTXSID90236013 ;
Chemical and physical data
Formula	C19H27N3O3S
Molar mass	377.501 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N1C(=O)\C(=C(\O)c2ccsc12)C(=O)NCCCN3CCCCC3;
	InChI InChI=1S/C19H27N3O3S/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21/h7,12-13,23H,3-6,8-11H2,1-2H3,(H,20,24); Key:SCHKZZSVELPJKU-UHFFFAOYSA-N;

PRX-03140 is a partial agonist (18% relative to 5-HT^[1]) of the 5-HT₄ receptor that is being developed by EPIX Pharmaceuticals for Alzheimer's disease.^[2]

References

^ Shen F, Smith JA, Chang R; et al. (2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ Shen, F (August 2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. {{cite journal}}: |access-date= requires |url= (help)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.